Our dedicated team of GPCR experts will enable drug screening with assays tailored to your specific needs:
1. Define the needs and scope for the project together with our assay development team.
2. Make us familiar with the goals for your research project and define timelines to ensure goal-oriented work right from the start.
3. We will acquire or generate a cell line appropriate to the project needs.
4. The same high standards we use for our off-the-shelf assays will apply to newly developed assays for your project.
5. We guarantee fast turn-around times for data generation.
6. During every step of the process, you will be in close contact with your project manager for regular updates on the study progress.
Cells engineered to express Gq-coupled receptors of interest are stimulated with a receptor agonist to elicit the generation of IP3. Given that IP3 is not metabolically stable, a surrogate marker of pathway activation (the metabolically stable IP1 (inositol 1-monophosphate) is measured. IP1 can be conveniently quantified using a TR-FRET-based competitive immunoassay as depicted above.
IP1 generation was quantified upon GPCR induction on an undisclosed agonist. Shown is also the IP1 standard curve for comparison.
Cells engineered to express Gs-coupled GPCRs of interest are stimulated with an agonist to affect cellular activation. cAMP can be accurately measured by a variety of standard detection methods including a competitive immunoassay wherein cellular cAMP competes with a labeled cAMP probe to bind to an anti-cAMP-cryptate generating a FRET signal.
Levels of cAMP were measured after stimulation of a GPCR expressing cell line with an undisclosed agonist. A cAMP standard curve is used for data normalization.
CHO (Chinese hamster ovary) cells engineered to express the receptor of interest are loaded with the calcium-sensitive dye Fluo-8 AM. Test compounds are added and fluorescence changes in the cells are monitored over time.
The concentration-response of agonist stimulation for calcium mobilization is shown.
ß-arrestins bind to activated GPCRs to mediate desensitization and internalization of GPCRs. They are scaffolding proteins that further mediate cell signaling pathways independent of G-proteins.
Example of ß-arrestin translocation in response to treatment with an undisclosed agonist.